Ublituximab in relapsing forms of multiple sclerosis: a profile of its use

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest Hannah A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here. 

Abstract Ublituximab (BRIUMVI™), an anti-CD20 immunoglobulin G1 monoclonal antibody, is a promising new treatment option for patients with relapsing forms of multiple sclerosis (MS). Ublituximab is approved in the USA and the EU for the treatment of adult patients with relapsing forms of MS. Following a starting dose of 150 mg infused over 4 h, ublituximab is conveniently administered twice-yearly as a short (1 h) intravenous infusion. In phase 3 clinical trials in patients with relapsing MS, ublituximab was more effective than oral teriflunomide at reducing annualized relapse rates and numbers of brain lesions over a period of 96 weeks. However, ublituximab did not result in a significantly lower risk of worsening of disability. Ublituximab had an acceptable tolerability profile in clinical trials. The most commonly reported adverse events were infusion-related reactions (IRRs), which occurred in almost half of ublituximab recipients. However, the majority of IRRs were of mild to moderate severity, occurred after the first dose and decreased in frequency with subsequent dosing.

© Springer Nature Switzerland AG 2023